Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas

Clinical Cancer Research

Volumn 15, Issue 17, 2009, Pages 5457-5465

  Elias, Agnes ^a   Siegelin, Markus D ^a   Steinmüller, Albert ^a   Von Deimling, Andreas ^a,b   Lass, Ulrike ^b   Korn, Bernhard ^b   Mueller, Wolf ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIINFECTIVE AGENT; CELL SURFACE PROTEIN; DEATH RECEPTOR 4; LEXATUMUMAB; MAPATUMUMAB; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; ASTROCYTE; ASTROCYTOMA; CELL LINE; CELL SURFACE; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; GENE CONTROL; GENE IDENTIFICATION; GENE SILENCING; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; WORLD HEALTH ORGANIZATION;

APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; GLIOMA; HUMANS; PROMOTER REGIONS, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 69949106920     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1125     Document Type: Article

References (28)

1. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054 (Pubitemid 37448928)
2. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-1354 (Pubitemid 30826035)
3. 6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189-4199
4. Martinez R, Schackert G, Yaya-Tur R, Rojas- Marcos I, Herman JG, Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol 2007;83:91-93 (Pubitemid 46647170)
5. Martinez R, Setien F, Voelter C, et al. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis 2007;28:1264-1268 (Pubitemid 47062686)
6. Bibikova M, Lin Z, Zhou L, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res 2006;16:383-393 (Pubitemid 43327509)
7. Fan JB, Gunderson KL, Bibikova M, et al. Illumina universal bead arrays. Methods Enzymol 2006;410:57-73.
8. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:808-815 (Pubitemid 34887244)
9. de Vries EG, Gietema JA, de Jong S. Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. Clin Cancer Res 2006;12:2390-2393
10. Capper D, Gaiser T, Hartmann C, et al. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol 2009;.
11. Siegelin MD, Habel A, Gaiser T. 17-AAG sensitized malignant gliomacells to death-receptor mediated apoptosis. Neurobiol Dis 2009;33:243-249
12. Louis DN, Ohgaki H, Wiestler OD, Cavenee KC, editor. WHO Classification of tumours of the central nervous system. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2007.
13. Mueller W, Nutt CL, Ehrich M, et al. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 2007;26:583-593 (Pubitemid 46160971)
14. Lorente A, Mueller W, Urdangarin E, et al. RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol 2009;19:279-292
15. Lorente A, Mueller W, Urdangarin E, Lazcoz P, von Deimling A, Castresana JS. Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR. BMC Cancer 2008;8:61.
16. Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene 2008;27:490-498
17. Ren YG, Wagner KW, Knee DA, Aza-Blanc P, Nasoff M, Deveraux QL. Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell 2004;15:5064-5074 (Pubitemid 39392220)
18. Wang S, El-Deiry WS. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 2004;64:6666-6672 (Pubitemid 39297928)
19. Martin-Subero JI, Kreuz M, Bibikova M, et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic and transcriptional profiling. Blood 2008.
20. Rohn TA,Wagenknecht B, Roth W, et al. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 2001;20:4128-4137 (Pubitemid 32762187)
21. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008;118:1979-1990 (Pubitemid 351872316)
22. Horak P, Pils D, Haller G, et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 2005;3:335-343 (Pubitemid 40905625)
23. Aguilera DG, Das CM, Sinnappah-Kang ND, et al. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J Neurooncol 2009;.
24. Reis CR, van der Sloot AM, Szegezdi E, et al. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry 2009;48:2180-2191
25. Kim EH, Kim SU, Shin DY, Choi KS. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004;23:446-456
26. Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene 2001;20:5789-5798 (Pubitemid 32937948)
27. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-5877 (Pubitemid 32937956)
28. Ashley DM, Riffkin CD, Muscat AM, et al. Caspase 8 is absent or low in many ex vivo gliomas. Cancer 2005;104:1487-1496